Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (DORDOL)
Combination antiretroviral therapy (cART) HIV treatments are associated with increased quality of life, and a normalisation of life expectancy in people living with HIV. However, long-term use of cART can lead to side-effects through exposure to drug-related toxicity. For this reason researchers are interested in looking at alternative therapies that might expose patients to fewer and less severe side effects while providing the same quality of care as antiretroviral therapies most often used to treat HIV. The purpose of this study is to investigate if the study drug combination that is being tested (doravirine + dolutegravir) is safe compared with other triple cART regimens.
• HIV-1 infected, 18 years or older
• On stable \& suppressive triple cART for at least 6 months
• No evidence of resistance to DOR or DTG
• No laboratory abnormalities, medical/psychiatric conditions or alcohol/drug use considered a barrier to participation by investigators
• Women who are pre-menopausal and sexually active should be on one of the following methods of contraception:
‣ Implant
⁃ Depot injection
⁃ Intra-uterine device or system
⁃ Oral hormonal contraception